期刊文献+

mDRA-6与尼美舒利对人肝癌细胞系SMMC-7721细胞的协同杀伤效应 被引量:1

Synergistic Lethal Effect of mDRA-6 and Nimesulide on Human Hepatocellular Cancer Cell Line SMMC-7721
下载PDF
导出
摘要 背景与目的:mDRA-6为本实验室制备的具有肿瘤细胞杀伤作用的抗人死亡受体5(death receptor5,DR5)的单克隆抗体,尼美舒利作为特异性环氧合酶-2(cyclooxygenase-2,COX-2)抑制剂,近年来发现其对某些肿瘤细胞系的细胞具有促凋亡作用,本研究探讨mDRA-6与尼美舒利对肝癌细胞系SMMC-7721的杀伤作用,及二者有无协同效应。方法:流式细胞术检测细胞表面DR5的表达率;分别用一定浓度的mDRA-6、尼美舒利、mDRA-6联合200μmol/L尼美舒利处理SMMC-7721细胞,MTT法检测细胞毒性作用,Hoechst33258染色观察SMMC-7721细胞核形态变化,流式细胞术定量分析凋亡细胞率。结果:SMMC-7721细胞表面DR5的表达率为95.0%,mDRA-6能够诱导SMMC-7721细胞凋亡,存在浓度依赖性(r=0.984,P=0.002),25ng/mL作用12h可杀伤10.5%的细胞,1600ng/mL作用12h可杀伤35.0%的细胞。尼美舒利能够诱导SMMC-7721细胞凋亡,200μmol/L作用12h可使5.0%的细胞凋亡,800μmol/L作用12h可杀伤34.0%的细胞,存在浓度依赖性(r=0.929,P=0.002)。尼美舒利与mDRA-6联合对SMMC-7721细胞具有协同杀伤作用(q=1.23),200μmol/L的尼美舒利协同25ng/mL与1600ng/mL的mDRA-6作用12h可分别杀伤31.2%与91.1%的SMMC-7721细胞,Hoechst33258染色和Annexin V/PI染色证实杀伤作用是通过诱导细胞凋亡实现的。结论:mDRA-6与尼美舒利均有杀伤SMMC-7721细胞的作用,二者具有协同作用,该作用是通过诱导凋亡实现的。 BACKGROUND & OBJECTIVE, Both mDRA-6, a monoclonal antibody of death receptor 5 (DR5) in human cells prepared by our key laboratory, and nimesulide, a specific cyclooxygenase-2 (COX-2) inhibitor, can induce apoptosis of some malignant tumor cells. This study was to investigate the lethal effects of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721, and explore the possible mechanism. METHODS: The expression of DR5 on SMMC-7721 cells was detected by flow cytometry (FCM). SMMC-7721 cells were treated with mDRA-6 and nimesulide alone or in combination. Cell morphology was observed under microscope with Hoechst33258 staining. Cytotoxicity was examined by MTT assay. Cell apoptosis was detected by FCM. RESULTS. The positive rate of DR5 on SMMC-7721 cells was 95.0%. The apoptosis of SMMC-7721 cells could be induced by both mDRA-6 and nimesulide: the apoptosis rates were 10.5% when treated with 25 ng/mL mDRA-6 for 12 h, 35.0% when treated with 1 600 ng/mL mDRA-6, 5.0% when treated with 200 μmol/L nimesulide, and 34.0% when treated with 800 μol/L nimesulide. The combination of mDRA-6 and nimesulide exhibited synergistic effect on the apoptosis of SMMC-7721 cells (q=1.23): the apoptosis rates were 31.2% when treated with 200 iJmol/L nimesulide and 25 ng/mL mDRA-6 for 12 h, and 91.1% when treated with 200 iJmol/L nimesulide and 1 600 ng/mL mDRA-6 for 12 h. CONCLUSIONS. Both mDRA-6 and nimesulide can induce the apoptosis of SMMC-7721 cells. The combination of mDRA-6 and nimesulide exhibits synergistic lethal effect on SMMC-7721 cells.
出处 《癌症》 SCIE CAS CSCD 北大核心 2008年第4期374-378,共5页 Chinese Journal of Cancer
关键词 抗人DR5单克隆抗体 尼美舒利 协同杀伤作用 凋亡 SMMC-7721细胞 Anti-human DR5 monoclonal antibody Nimesulide Synergistic effect Apoptosis SMMC-7721 cells
  • 相关文献

参考文献19

  • 1Wiley S R, Schooley K, Smolak P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis [J]. Immunity, 1995,3(6) :673-682.
  • 2Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity [J]. Nat Med, 2001,7(8) :954-960.
  • 3Takeda K, Yamaguchi N, Akiba H, et al. Induction of tumorspecific T cell immunity by anti-DR5 antibody therapy [J]. J Exp Med, 2004, 199(4) :437-448.
  • 4LeBlanc H N, Ashkenazi A. Apo2L/TRAIL and its death and decoy recptors [J]. Cell Death Differ, 2003,10( 1 ) : 66-75.
  • 5Pan G, Ni J, Wei Y F, et al. An antagonist decoy receptor and death domain-containing receptor for TRAIL [J]. Science, 1997,277(5327 ) : 815-818.
  • 6Pitti R M, Marsters S A, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family [J]. J Biol Chem, 1996,271 (22) : 12687-12690.
  • 7Mongkolsapaya J, Grimes J M, Chen N, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation [J]. Nat Struct Biol, 1999,6 (11 ) : 1048-1053.
  • 8Walczak H, Miller R E, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptos-inducing ligand in vivo [J]. Nat Med, 1999,5(2) : 157-163.
  • 9Howe L R, Dannenberg A J. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer [J]. Semin Oncol, 2002,29 (3 Suppl 11 ) : 111 - 119.
  • 10Soslow R A, Dannenberg A J, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors [ J ]. Cancer, 2000,89 (12) : 2637-2645.

二级参考文献11

  • 1范跃祖,傅锦业,赵泽明,陈春球.去甲斑蝥素对人胆囊癌GBC-SD细胞系生长的影响及其机制探讨[J].肿瘤,2004,24(4):358-361. 被引量:8
  • 2付启良 杨梅芳 等.前列腺素E(PGE)与胃癌[J].中华肿瘤杂志,1986,8(5):345-345.
  • 3Leng J, Han C, Demetris AJ, et al. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for akt inhibition in celecoxib-induced apoptosis [J]. Hepatology, 2003, 38(3): 756-764.
  • 4Williams CS, Mann M, DuBois RN. The role of cyclooxygenase in inflammation, cancer and development [J]. Oncogene, 1999, 18(55): 7908-7916.
  • 5Shin S, Sung BG, Chao YS, et al. An anti-apoptosis protein human Survivin is a direct inhibitor of Caspase-3 and-7 [J]. Biochemistry, 2001, 40(4): 1117-1123.
  • 6Yamazaki R, Kusonoli N, Matsuzaki T, et al. Selective cyclooxygenase-2 inhibitors show a different ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells[J]. FEBS Lett,2002, 531(2): 278-284.
  • 7Eibl G, Reber HA, Wente MN, et al. The selective cyclooxygenase--2 inhibitor nimesulide induce apoptosis in pancreatic cancer cells independent of COX-2[J]. Pancreas, 2003, 26(1): 33-41.
  • 8Mandhu SS, Abhijit C, Mandip S. Effect of selective cyclooxygenase-2 inhibitor, nimesulide,on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator activated receptor-γ[J]. Glin Cancer Res, 2004, 10(4):1521-1529.
  • 9Devereaux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell death proteases [J]. Nature, 1997, 388(6639): 300 -304.
  • 10Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene,Survivin, expressed in cancer and lymphoma[J]. Nat Med, 1997, 3(8): 917-921.

共引文献33

同被引文献7

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部